235 related articles for article (PubMed ID: 14738147)
1. Low dose thalidomide in patients with relapsed or refractory multiple myeloma.
Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H
Leuk Lymphoma; 2003 Nov; 44(11):1943-6. PubMed ID: 14738147
[TBL] [Abstract][Full Text] [Related]
2. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.
Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K
Semin Hematol; 2003 Oct; 40(4 Suppl 4):3-7. PubMed ID: 15015890
[TBL] [Abstract][Full Text] [Related]
4. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
5. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou M; Mitsouli Ch; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A;
Ann Oncol; 2004 Jan; 15(1):134-8. PubMed ID: 14679133
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
[TBL] [Abstract][Full Text] [Related]
7. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
[TBL] [Abstract][Full Text] [Related]
8. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide.
Hussein MA
Oncologist; 2003; 8 Suppl 3():39-45. PubMed ID: 14671227
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide and dexamethasone combination for refractory multiple myeloma.
Dimopoulos MA; Zervas K; Kouvatseas G; Galani E; Grigoraki V; Kiamouris C; Vervessou E; Samantas E; Papadimitriou C; Economou O; Gika D; Panayiotidis P; Christakis I; Anagnostopoulos N
Ann Oncol; 2001 Jul; 12(7):991-5. PubMed ID: 11521808
[TBL] [Abstract][Full Text] [Related]
10. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
[TBL] [Abstract][Full Text] [Related]
13. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.
Kwon J; Min CK; Kim K; Han JJ; Moon JH; Kang HJ; Eom HS; Kim MK; Kim HJ; Yoon DH; Lee JO; Lee WS; Lee JH; Lee JJ; Choi YS; Kim SH; Yoon SS
Cancer Med; 2017 Jan; 6(1):100-108. PubMed ID: 27905203
[TBL] [Abstract][Full Text] [Related]
15. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma.
García-Sanz R; González-Fraile MI; Sierra M; López C; González M; San Miguel JF
Hematol J; 2002; 3(1):43-8. PubMed ID: 11960395
[TBL] [Abstract][Full Text] [Related]
16. [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma].
Gao W; An N; Chen SL
Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):221-2. PubMed ID: 16624158
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
18. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.
Dimopoulos MA; Hamilos G; Zomas A; Gika D; Efstathiou E; Grigoraki V; Poziopoulos C; Xilouri I; Zorzou MP; Anagnostopoulos N; Anagnostopoulos A
Hematol J; 2004; 5(2):112-7. PubMed ID: 15048060
[TBL] [Abstract][Full Text] [Related]
19. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
[TBL] [Abstract][Full Text] [Related]
20. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.
Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK
Leuk Lymphoma; 2003 Jul; 44(7):1147-9. PubMed ID: 12916866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
